Reliability of self-reported real-world psychedelic use – A test-retest study in a population sample
Karilynn M Rockhill, Nicole Schow, Dean Garibaldi, Andrew A. Monte, Joshua Curtis Black
Psychedelics September 29, 2026 DOI: 10.1016/j.psyche.2026.100040 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Test-retest reliability sub-study of a survey Peer reviewed |
|---|---|
| Sample size | 690 |
| Population | Adults sampled from the National Survey Investigating Hallucinogenic Trends (NSIHT) in 2024 |
| Duration | Use in the last 12 months; retest interval not stated |
| Measures | Gwet's AC1, overall agreement, average positive/negative agreement, mixed effects logistic regression |
| Key findings | Self-reported use of 17 psychedelic and dissociative substances showed substantial to excellent test-retest reliability (Gwet's AC1 all at least 0.73, average 0.87; overall agreement all at least 85.1%, average 90.4%). Reliability was driven by consistent reporting of no use, and reliability for yes answers declined as prevalence of use declined. Adjusted probabilities of reliable reporting of reasons and recency of use were 0.96 to 0.98. |
Abstract
Objective: In 2024, the United States had the highest prevalence of psychedelic use recorded, but reliability of self-report data in surveys has not been rigorously assessed. Our objective was to quantify the reliability of self-report across 17 psychedelic and dissociative substances in an adult population sampled from the National Survey Investigating Hallucinogenic Trends (NSIHT).
Methods: In 2024, a test-retest sub-study was conducted on NSIHT. Overall agreement, average positive/negative agreement, and Gwet’s AC1 were calculated for use in the last 12 months. Reason and recency of use reliability was assessed through separate mixed effects logistic regressions models adjusting for all substances used and other reasons for use.
Results: There were 690 of 2,023 respondents (34.1%) who returned to the retest sample; there were minimal differences in demographics or none in health metrics of respondents and non-respondents. Across 17 substances, use showed “substantial” to “excellent reliability” indicated by Gwet’s AC1 (all ≥0.73, average 0.87), overall agreement (all ≥85.1%, average 90.4%). Overall agreement was driven by reliable report of “no” use of substances. Reliability for “yes” use decreased alongside decreasing prevalence of use. After adjustment, the probability of a reliable answer for all reported reasons and recency of use were 0.96 to 0.98.
Conclusions: This is the first study to demonstrate substantial to excellent reliability based on Gwet’s AC1 across 17 self-reported psychedelic and dissociative substances for use and behaviors. Methodological rigor and transparency allow for generation of trustworthy, reliable estimates and for the field to accurately interpret and compare findings across studies.
Citations in the library
Cites 7
- Psychedelics. Current Biology 2022
- Psychedelic therapies reconsidered: compounds, clinical indications, and cautious optimism. Neuropsychopharmacology July 21, 2023
- 2018: A watershed year for psychedelic science Drug Science, Policy and Law 2019
- Public Interest in Psilocybin and Psychedelic Therapy in the Context of the COVID-19 Pandemic: Google Trends Analysis JMIR Formative Research November 28, 2023
- Fusing Specialized Surveys of Rare Populations to Larger Surveys for Generalized Inference: Cross-Sectional Survey Study. Journal of Medical Internet Research April 27, 2026
and 2 more in the library